Background International guidelines do not provide uniform recommendations regarding the
use of antiplatelet treatment in the perioperative period in patients undergoing coronary …

Background Randomized controlled trials have shown a reduced risk of ischemic events
and an increased risk of bleeding in patients treated with prolonged dual anti-platelet …

The optimal duration and cancer risks of antiplatelet therapy following percutaneous
coronary intervention (PCI) are unclear. We compared cancer and all-cause mortality after …

Background: Antiplatelet therapy is critical in the management of coronary artery disease.
For patients undergoing coronary artery bypass graft surgery (CABG), controversy remains …

Background Antiplatelet agents are central in the management of vascular disease. The use
of dual antiplatelet therapy (DAPT) for the management of thromboembolic complications …

OBJECTIVES Acetylsalicylic acid (ASA) monotherapy is the standard of care after coronary
artery bypass grafting (CABG), but the benefits of more intense antiplatelet therapy …

OBJECTIVES: An increasing number of patients are referred for coronary artery bypass graft
surgery while treated with clopidogrel. This agent inhibits the platelet P2Y12 adenosine-5 …

Background Clopidogrel was superior to aspirin monotherapy in secondary prevention after
percutaneous coronary intervention (PCI). Objectives The purpose of this study was to …

Clopidogrel is recommended with aspirin for patients who undergo coronary artery bypass
grafting (CABG) after non–ST elevation myocardial infarctions. Cardiothoracic surgeons …

For several years, clopidogrel plus aspirin has been the dual antiplatelet therapy (DAPT) of
choice for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary …